Skip to content
Pharma Observatory a Scientist.com platform

Organization (Academic)

Aga Khan University

ClinicalTrials.gov lists Aga Khan University as lead sponsor of 293 trials. It has 44 active development programs and 66 approved assets.

TZ Academic
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

32 0 1995 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 24 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 27 in 2026 and about 23 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

This page covers Aga Khan University: 293 lead-sponsored trials and 2 legal-entity registrations. Part of Aga Khan Development Network.

Get the Aga Khan University report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (213)

Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).

Disease areas
Disease area Trials
Malnutrition 29
Hypertension 19
Anemia 18
Death 17
Growth Disorders 15

Trials by start year as sponsor or collaborator (27)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 24
2025 19
2024 24
2023 24
2022 21
2021 22
2020 30
2019 32
2018 19
2017 19

Prediction, not a registry value: median of 30 months from start to primary completion across 20 trials still running at the 2026-10-09 snapshot; registered median of 14 months across 167 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (44)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Calcium/Vitamin D Malnutrition Phase 2 2
Calcium/Vitamin D Vitamin D Deficiency Phase 2 2
Calcium/Vitamin D Infertility Phase 2 1
VE818 Growth Disorders Phase 2 1
Oral Vancomycin Growth Disorders Phase 2 1

Approved assets (66)

Shown in this order: max phase first.

Approved assets
Drug Trials
Amoxicillin 3
Carvedilol 2
Metronidazole Gel 2
bOPV 2
Saccharomyces boulardii 2

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
65% hit target (n=48) 35% on time (n=51)

Biomarker capability evidence (88)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ALB Trial sponsor Named in trial inclusion criteria
CEACAM5 Trial sponsor Named in trial inclusion criteria
DMD Trial sponsor Named in trial inclusion criteria
EIF2AK2 Trial sponsor Named in trial inclusion criteria
G6PD Trial collaborator Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and clia clinical laboratory certificates.

Counted at group level under Aga Khan Development Network: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.